Darzalex (Daratumumab) is a new FDA approved immunotherapy treatment for multiple myeloma.

This cancer treatment is currently approved specifically to treat patients who have received at least three or more previous types of myeloma treatments.

According to recent studies, Darzalex is showing great promise and is improving progression free survival, which is the length of time during and after treatment that patients live with cancer, but it does not become worse.

In a new video on Darzalex, oncologist describes how this cancer treatment works and also explains what types of side effects it may cause.

Multiple myeloma is a blood cancer that originates in the plasma cells, which are located within the bone marrow. When these plasma cells are malignant, or cancerous, they produce too much protein, which may eventually crowd out and destroy healthy plasma, causing damage to the bones, anemia, elevated calcium in the blood, kidney problems, as well as other symptoms.

As part of the body’s immune system, normal, non-malignant plasma cells produce healthy antibodies that help the body fight off possible infections.

Developed by Janssen Biotech, Darzalex is an antibody that attacks these myeloma cells (malignant plasma cells) and destroys them, helping to control muliple myeloma and preventing it from getting worse and causing damage to the bones, bone marrow and the kidneys.

Please visit our Darzalex treatment page to learn more about this treatment or to watch the video.